Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 18 July are set out below…

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 18 July are set out below…
A new development in New Zealand will provide an option for a faster route to judgment in patent and other intellectual property litigation. From 1 October 2025, a Commercial…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 11 July are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 4 July are set out below…
On 5 February 2025, Justice Downes of the Federal Court of Australia delivered her decision in the dispute between Otsuka Japan and its licensees (Lundbeck A/S and Australia and Otsuka Australia) (collectively…
A new development in New Zealand will provide an option for a faster route to judgment in patent and other intellectual property litigation. From 1 October 2025, a Commercial…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 June are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 June are set out below…
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 June are set out below…
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
We are thrilled to announce that 6 Pearce IP patent professionals have again been recognised by Managing IP in the 2025 MIP IP STARS, a leading global guide to the top intellectual property firms and practitioners.
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 June are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 30 May are set out below…
Pearce IP Recognised in Best Law Firms 2026!
The Full Court of the Federal Court has delivered judgment in the proceedings between Motorola Solutions Inc (Motorola) and Hytera Communications Corporation Ltd (Hytera), in their ongoing…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 16 May are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 9 May are set out below…
Pearce IP’s Founder and CEO Naomi Pearce is a finalist in two categories of the 2025 Lawyers Weekly Partner of the Year Awards: Senior Partner of the Year – 15 Years or More...
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 2 May are set out below…
Sally Paterson Joins Pearce IP – Executive Lawyer, Patent and Trade Mark Attorney
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.